ArticleTranslational cancer research2026
Epcoritamab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: how should this regimen be positioned in current treatment algorithms?
Mariko Tsuda et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.